1. Home
  2. ADNT vs PVLA Comparison

ADNT vs PVLA Comparison

Compare ADNT & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adient plc

ADNT

Adient plc

HOLD

Current Price

$20.40

Market Cap

1.5B

ML Signal

HOLD

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$138.01

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADNT
PVLA
Founded
2016
2015
Country
Ireland
United States
Employees
N/A
29
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
ADNT
PVLA
Price
$20.40
$138.01
Analyst Decision
Buy
Strong Buy
Analyst Count
11
15
Target Price
$25.41
$171.87
AVG Volume (30 Days)
1.1M
285.1K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$17,439,000,000.00
N/A
Revenue This Year
$2.71
N/A
Revenue Next Year
$2.36
$104,350.18
P/E Ratio
$335.17
N/A
Revenue Growth
7.56
N/A
52 Week Low
$17.68
$34.57
52 Week High
$27.32
$161.38

Technical Indicators

Market Signals
Indicator
ADNT
PVLA
Relative Strength Index (RSI) 51.93 50.98
Support Level $19.96 $106.07
Resistance Level $21.76 $156.88
Average True Range (ATR) 0.75 11.22
MACD 0.20 -1.80
Stochastic Oscillator 87.38 52.02

Price Performance

Historical Comparison
ADNT
PVLA

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Share on Social Networks: